Chemotherapy-induced neutropenia as a prognostic factor in patients with unresectable pancreatic cancer

Cancer Chemotherapy and Pharmacology

Volumn 76, Issue 6, 2015, Pages 1217-1224

  Kurihara, Tatsuya ^a   Kogo, Mari ^a   Ishii, Masakazu ^a   Shimada, Ken ^a   Yoneyama, Keiichiro ^a   Kitamura, Katsuya ^b   Shimizu, Shunichi ^a   Yoshida, Hitoshi ^b   Kiuchi, Yuji ^a  

^a SHOWA UNIVERSITY   (Japan)

^b SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Gemcitabin; Neutropenia; Prognosis; Unresectable pancreatic cancer

Indexed keywords

GEMCITABINE; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; COHORT ANALYSIS; DRUG EFFICACY; FEMALE; HUMAN; INOPERABLE CANCER; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; NEUTROPHIL COUNT; OVERALL SURVIVAL; PANCREAS CANCER; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; SURVIVAL TIME; AGED; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; DISEASE FREE SURVIVAL; MIDDLE AGED; OUTCOME ASSESSMENT; PANCREATIC NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDY; STATISTICS AND NUMERICAL DATA; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUTROPENIA; OUTCOME ASSESSMENT (HEALTH CARE); PANCREATIC NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES;

EID: 84947586769     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-015-2887-4     Document Type: Article

References (38)

1. Jemal A, Bray F, Center MM et al (2011) Global cancer statistics. CA Cancer J Clin 61:69-90
2. Ahlgren JD (1996) Chemotherapy for pancreatic carcinoma. Cancer 78:654-663
3. Bramhall SR, Rosemurgy A, Brown PD et al (2001) Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. J Clin Oncol 19:3447-3455
4. Heinemann V, Quietzsch D, Gieseler F et al (2006) A phase III trial comparing gemcitabine plus cisplatine compared with gemcitabine alone in advanced pancreatic adenocarcinoma. J Clin Oncol 24:3946-3952
5. Van Cutsem E, van de Velde H, Karasek P et al (2004) Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 22:1430-1438
6. Oettle H, Richards D, Ramanathan RK et al (2005) A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Ann Oncol 10:1639-1645
7. Louvet C, Labianca R, Hammel G et al (2005) Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Cin Oncol 23:3509-3516
8. Reni M, Cordio S, Milandri C et al (2005) Gemcitabine versus cisplatin, epirubicin, fluorouracil and gemcitabine in advanced pancreatic cancer: a randomised controlled multicenter phase III trial. Lancet Oncol 6:369-376
9. Moore MJ, Goldstein D, Hamm J et al (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1960-1966
10. Cunningham D, Chau I, Stocken DD et al (2009) Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol 27:5513-5518
11. Rocha Lima CMS, Green MR, Rotche R et al (2004) Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol 22:3776-3783
12. Conroy T, Desseigne F, Ychou M et al (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364:1817-1825
13. Von Hoff DD, Ervin T, Arena FP et al (2013) Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369:1691-1703
14. Yamaguchi K, Okusaka T, Shimizu K et al (2014) EBM-based Clinical Guidelines for Pancreatic Cancer (2013) issued by the Japan Pancreas Society: a synopsis. Jpn J Clin Oncol 44:883-888
15. Saarto T, Blomqvist C, Rissanen P, Auvinen A, Elomaa I (1997) Haematological toxicity: a marker of adjuvant chemotherapy efficacy in stage II and III breast cancer. Br J Cancer 75:301-305
16. Cameron DA, Massie C, Kerr G, Leonard RC (2003) Moderate neutropenia with adjuvant CMF confers improved survival in early breast cancer. Br J Cancer 89:1837-1842
17. Di Maio M, Gridelli C, Gallo C et al (2005) Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of three randomised trials. Lancet Oncol 6:669-677
18. Pallis AG, Agelaki S, Kakolyris S et al (2008) Chemotherapy-induced neutropenia as a prognostic factor in patients with advanced non-small cell lung cancer treated with front-line docetaxel-gemcitabine chemotherapy. Lung Cancer 62:356-363
19. Carus A, Gurney H, Gebski V et al (2013) Impact of baseline and nadir neutrophil index in non-small cell lung cancer and ovarian cancer patients: assessment of chemotherapy for resolution of unfavourable neutrophilia. J Transl Med 11:189
20. Yamanaka T, Matsumoto S, Teramukai S, Ishiwata R, Nagai Y, Fukushima M (2007) Predictive value of chemotherapy-induced neutropenia for the efficacy of oral fluoropyrimidine S-1 in advanced gastric carcinoma. Br J Cancer 97:37-42
21. Shitara K, Matsuo K, Takahari D et al (2009) Neutropaenia as a prognostic factor in metastatic colorectal cancer patients undergoing chemotherapy with first-line FOLFOX. Eur J Cancer 45:1757-1763
22. Sunaga T, Suzuki S, Kogo M et al (2014) The association between neutropenia and prognosis in stage III colorectal cancer patients receiving adjuvant chemotherapy. Eur J Cancer Care (Engl) 23:394-400
23. Rocconi RP, Matthews KS, Kemper MK et al (2008) Chemotherapy-related myelosuppression as a marker of survival in epithelial ovarian cancer patients. Gynecol Oncol 108:336-341
24. Dodwell DJ, Gurney H, Thatcher N (1990) Dose intensity in cancer chemotherapy. Br J Cancer 61:789-794
25. Ueno H, Okada S, Okusaka T et al (2000) Prognostic factors in patients with metastatic pancreatic adenocarcinoma receiving systemic chemotherapy. Oncology 59:296-301
26. Louvet C, Labianca R, Hammel G et al (2005) Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Cin Oncol 23:3509-3516
27. Maréchal R, Demols A, Gay F et al (2007) Prognostic factors and prognostic index for chemonaïve and gemcitabine-refractory patients with advanced pancreatic cancer. Oncology 73:41-51
28. Sawaki A, Kanemitsu Y, Mizuno N et al (2008) Practical prognostic index for patients with metastatic pancreatic cancer treated with gemcitabine. J Gastroenterol Hepatol 23:1292-1297
29. Tanaka T, Ikeda M, Okusaka T et al (2008) Prognostic factors in Japanese patients with advanced pancreatic cancer treated with single-agent gemcitabine as first-line therapy. Jpn J Clin Oncol 38:755-761
30. Kurihara T, Kogo M, Ishii M et al (2015) Practical Prognostic Index for survival in patients with unresectable pancreatic cancer treated with gemcitabine or S-1. Hepatogastroenterology 62:478-484
31. Yoneyama K, Katsumoto E, Kurihara T et al (2012) Factors predicting the appearance of neutropenia in patients with advanced pancreatic cancer undergoing gemcitabine therapy. Hepatogastroenterology 59:894-898
32. Frei E 3rd, Canellos GP (1980) Dose: a critical factor in cancer chemotherapy. Am J Med 69:585-594
33. Gurney H (2002) How to calculate the dose of chemotherapy. Br J Cancer 86:1297-1302
34. Newell DR (2002) Getting the right dose in cancer chemotherapy-time to stop using surface area? Br J Cancer 86:1207-1208
35. Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420:860-867
36. Helmut S, Oka M, Thomas B et al (2003) Differential response of primary and metastatic melanomas to neutrophils attracted by IL-8. Int J Cancer 103:335-343
37. Peter S, Jess DS, Ben JZP et al (2001) Activation of progelatinase A (MMP-2) by neutrophil elastase, cathepsin G, and proteinase-3: a role for inflammatory cells in tumor invasion and angiogenesis. J Cell Physiol 189:197-206
38. Ren G, Zhao X, Wang Y et al (2012) CCR2-dependent recruitment of macrophages by tumor-educated mesenchymal stromal cells promotes tumor development and is mimicked by TNFα. Cell Stem Cell 11:812-824